LakeShore Biopharma Receives Revised Lower Acquisition Offer from Oceanpine Skyline

LakeShore Biopharma Co., Ltd. announced that its special committee has received a revised preliminary non-binding proposal from Oceanpine Skyline Inc. to acquire the company. The new proposal suggests reducing the purchase price to $0.06 per ordinary share, marking a significant downward adjustment. This revision follows the terms of the original merger agreement dated November 4, 2025. The buyer group, including Oceanpine Merger Sub Inc., is seeking to renegotiate the valuation previously established for the transaction. As the proposal remains non-binding, there is no guarantee that a definitive agreement will be reached or that the merger will be completed. Market analysts view this price reduction as a bearish development for the company's stock, as it lowers the expected payout for existing shareholders.